Non-Small Cell Lung Cancer (NSCLC)

Investigators will submit full results from the REZILIENT3 trial assessing zipalertinib in EGFR-mutated NSLCC at a future international medical meeting.

The UAE granted marketing authorization for nogapendekin alfa plus BCG in BCG-unresponsive NMIBC and with checkpoint inhibitors in metastatic NSCLC.

Experts discuss how to properly select first-line regimens for EGFR-mutated NSCLC in the context of different clinical scenarios.

In a phase 3 trial, ensartinib raised the 24-month disease-free survival rate to 86.4% vs 53.5% with placebo in patients with resected ALK-positive NSCLC.

Findings from the global, single-arm phase 1/2 ARROS-1 trial in patients with advanced or metastatic ROS1-positive NSCLC support the regulatory decision.

Updated phase 3 HARMONi trial data show ivonescimab plus chemotherapy improves overall survival in Western and Asian EGFR-mutant NSCLC groups.

Data from the phase 3 OptiTROP-Lung06 trial also showed a positive trend in overall survival with sac-TMT plus pembrolizumab in patients with NSCLC.

Mature overall survival data from the INSIGHT-003 trial compare favorably with historical benchmarks in frontline NSCLC therapy.

Data from the phase 2 RECLAIM trial demonstrate the feasibility of a multimodal strategy in a patient population with limited therapeutic options.

Ateganosine plus cemiplimab showed an acceptable safety profile among patients with third-line NSCLC in the phase 2 THIO-101 trial.

Two teams of lung cancer experts face off to determine the optimal first-line treatment regimen in EGFR-mutated metastatic NSCLC.

Preliminary data from the phase 1/2 TARGET-D 101 trial showed a manageable safety profile for VS-7375 across KRAS G12D–mutated solid tumors.

Investigators will share detailed results from the phase 3 SigVie-002 trial assessing sigvotatug vedotin in NSCLC at a future medical meeting.

Binimetinib tablets at 45 mg received tentative FDA approval for patients with melanoma and NSCLC.

A recommendation from the external data monitoring committee led to the discontinuation of the phase 3 KEYNOTE D46/EVOKE-03 study.

Cancer-related survival was similar among patients with PD-L1–positive or PD-L1–negative NSCLC who received durvalumab.

The FLAME trial showed osimertinib plus carboplatin/pemetrexed significantly improved PFS vs osimertinib monotherapy in ctDNA-persistent EGFR-mutant NSCLC.

The role of adjuvant immunotherapy remains unclear in this NSCLC population following data from the phase 3 ALCHEMIST trial.

Seven-year data from the CROWN study show improved PFS with lorlatinib over crizotinib among patients with ALK-positive non–small cell lung cancer.

The phase 3 HARMONi-6 trial showed ivonescimab plus chemotherapy significantly improved OS vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Data from the phase 3 LIBRETTO-432 study may support adjuvant selpercatinib as a new standard of care in this NSCLC population.

Data from the phase 1/1b CHRYSALIS-2 trial show enduring responses with amivantamab plus lazertinib in this EGFR-mutated NSCLC population.

The objective response rate was significantly higher with sac-TMT plus pembrolizumab vs pembrolizumab alone in the phase 3 OptiTROP-Lung05 trial.

The FDA has assigned a Prescription Drug User Fee Act date of November 27, 2026, for neladalkib in this ALK-positive non–small cell lung cancer population.

Developers intend to submit a supplemental new drug application for toripalimab/chemotherapy in resectable stage II or III NSCLC.